Second trimester maternal serum biomarkers and the risk of cerebral palsy.
Journal
Prenatal diagnosis
ISSN: 1097-0223
Titre abrégé: Prenat Diagn
Pays: England
ID NLM: 8106540
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
25
05
2021
received:
03
03
2021
accepted:
27
06
2021
pubmed:
17
7
2021
medline:
17
12
2021
entrez:
16
7
2021
Statut:
ppublish
Résumé
To investigate whether second trimester maternal serum screening (2TMSS) biomarkers are associated with cerebral palsy (CP) and identify CP characteristics associated with abnormal biomarker levels. In this retrospective case-control data linkage study, we linked mothers of 129 singleton CP cases from a population register to their 2TMSS records and selected 10 singleton pregnancy controls per case (n = 1290). We compared mean and abnormal levels of alpha-fetoprotein (AFP), beta subunit of human chorionic gonadotrophin (β-hCG), unconjugated estriol (uE3), and inhibin between cases and controls and within CP subgroups. Compared to control pregnancies, CP pregnancies had higher mean levels of AFP (1.10 vs. 1.01 multiple of the population median [MoM], p = 0.01) and inhibin (1.10 vs. 0.98 MoM, p ≤ 0.01). CP pregnancies were 2.5 times more likely to be associated with high levels of AFP (OR 2.52 [95% confidence interval [CI] 1.30, 4.65]; p < 0.01) and 2.6 times for inhibin (OR 2.63 [95% CI 1.37, 4.77]; p < 0.01), and 6.8 times when AFP and inhibin were both elevated (OR 6.75 [95% CI 2.41, 18.94]; p < 0.01). In CP cases, high AFP and high inhibin levels were associated with preterm birth and low birthweight. Abnormal second-trimester biomarker levels suggest abnormal placentation plays a role in the causal pathway of some CP cases.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1101-1110Subventions
Organisme : The Lorenzo and Pamela Galli Medical Research Trust
Organisme : The Royal Children's Hospital Foundation
Organisme : The Victorian Department Health and Human Services
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Rosenbaum P, Paneth N, Leviton A, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109:8-14.
Australian Cerebral Palsy Register Group, Smithers-Sheedy H, Waight E, McIntyre S. In: Thornton M, ed. Report of the Australian Cerebral Palsy Register Birth Years 1995-2012. Sydney: Cerebral Palsy Alliance Research Institute; 2018.
Carlson LM, Vora NL. Prenatal diagnosis: screening and diagnostic tools. Obstetrics Gynecol Clin N Am. 2017;44:245-256.
Mizejewski GJ. Biological roles of alpha-fetoprotein during pregnancy and perinatal development. Exp Biol Med. 2004;229:439-463.
Spear BT. Alpha-fetoprotein. In: Maloy S, Hughes K, eds. Brenner's Encyclopedia of Genetics. 2nd ed. San Diego, CA: Academic Press; 2013:89-91.
Nwabuobi C, Arlier S, Schatz F, Guzeloglu-Kayisli O, Lockwood CJ, Kayisli UA. hCG: Biological functions and clinical applications. Int J Mol Sci. 2017;18.
Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol. 2010;8:102.
Falah N, Torday J, Quinney SK, Haas DM. Estriol review: Clinical applications and potential biomedical importance. Clin Res Trials. 2015;1:29-33.
Luisi S, Florio P, Reis FM, Petraglia F. Inhibins in female and male reproductive physiology: role in gametogenesis, conception, implantation and early pregnancy. Hum Reprod Update. 2005;11:123-135.
Korzeniewski SJ, Slaughter J, Lenski M, Haak P, Paneth N. The complex aetiology of cerebral palsy. Nat Rev Neurol. 2018;14:528-543.
Sirikunalai P, Wanapirak C, Sirichotiyakul S, et al. Associations between maternal serum free beta human chorionic gonadotropin (beta-hCG) levels and adverse pregnancy outcomes. J Obstetr Gynaecol. 2016;36:178-182.
Yue CY, Zhang CY, Ni YH, Ying CM. Are serum levels of inhibin A in second trimester predictors of adverse pregnancy outcome? PLoS One. 2020;15:e0232634.
Lockwood GM, Ledger WL, Barlow DH, Groome NP, Muttukrishna S. Measurement of inhibin and activin in early human pregnancy: demonstration of fetoplacental origin and role in prediction of early-pregnancy outcome. Biol Reprod. 1997;57:1490-1494.
Florio P, Luisi S, D'Antona D, Severi FM, Rago G, Petraglia F. Maternal serum inhibin A levels may predict pregnancy outcome in women with threatened abortion. Fertil Steril. 2004;81:468-470.
Smithers-Sheedy H, Badawi N, Blair E, et al. What constitutes cerebral palsy in the twenty-first century? Dev Med Child Neurol. 2014;56:323-328.
Jaques AM, Collins VR, Haynes K, et al. Using record linkage and manual follow-up to evaluate the Victorian maternal serum screening quadruple test for Down's syndrome, trisomy 18 and neural tube defects. J Med Screen. 2006;13:8-13.
Wald NJ, Cuckle H, Brock JH, Peto R, Polani PE, Woodford FP. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet. 1977;1:1323-1332.
Cuckle H. Prenatal screening using maternal markers. J Clin Med. 2014;3:504-520.
Himmelmann K, Horber V, De La Cruz J, et al. MRI classification system (MRICS) for children with cerebral palsy: development, reliability, and recommendations. Dev Med Child Neurol. 2017;59:57-64.
Hu J, Zhang J, He G, et al. First-trimester maternal serum alpha-fetoprotein is not a good predictor for adverse pregnancy outcomes: a retrospective study of 3325 cases. BMC Pregn Childbirth. 2020;20:104.
Dugoff L, Hobbins JC, Malone FD, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstetr Gynecol. 2005;106.
Goetzinger KR, Odibo AO. Screening for abnormal placentation and adverse pregnancy outcomes with maternal serum biomarkers in the second trimester. Prenat Diagn. 2014;34:635-641.
Yuan W, Chen L, Bernal AL. Is elevated maternal serum alpha-fetoprotein in the second trimester of pregnancy associated with increased preterm birth risk? A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2009;145:57-64.
Goto E. Association of high maternal blood alpha-fetoprotein level with risk of delivering small for gestational age: a meta-analysis. Pediatr Res. 2020.
Morssink LP, Kornman LH, Beekhuis JR, de Wolf BTHM, Mantingh A. Abnormal levels of maternal serum human chorionic gonadotropin and alpha-fetoprotein in the second trimester: relation to fetal weight and preterm delivery. Prenat Diagn. 1995;15:1041-1046.
Waller K, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB. The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstetr Gynecol. 1996;88:816-822.
Tancrède S, Bujold E, Giguère Y, Renald M-H, Girouard J, Forest J-C. Mid-trimester maternal serum AFP and hCG as markers of preterm and term adverse pregnancy outcomes. J Obstetr Gynaecol Can. 2015;37:111-116.
Murphy DJ, Johnson AM, Sellers S, MacKenzie IZ. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet. 1995;346:1449-1454.
Lafuste P, Robert B, Mondon F, et al. Alpha-fetoprotein gene expression in early and full-term human trophoblast. Placenta. 2002;23:600-612.
Mizejewski GJ. Alpha-fetoprotein (AFP) and inflammation: is AFP an acute and/or chronic phase reactant? J Hematol Thromboembol Dis. 2015;3:1-9.
Hu J, Zhang J, Chan Y, Zhu B. A rat model of placental inflammation explains the unexplained elevated maternal serum alpha-fetoprotein associated with adverse pregnancy outcomes. J Obstetr Gynaecol Res. 2019;45:1980-1988.
Staff AC, Fjeldstad HE, Fosheim IK, et al. Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsia. Am J Obstetr Gynecol. 2020.
Lamarca B. Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia. Minerva Ginecol. 2012;64:309-320.
Zur RL, Kingdom JC, Parks WT, Hobson SR. The placental basis of fetal growth restriction. Obstetr Gynecol Clin N Am. 2020;47:81-98.
Rankin J, Cans C, Garne E, et al. Congenital anomalies in children with cerebral palsy: a population-based record linkage study. Dev Med Child Neurol. 2010;52:345-351.
Garne E, Dolk H, Krägeloh-Mann I, Holst Ravn S, Cans C. Cerebral palsy and congenital malformations. Eur J Paediatr Neurol. 2008;12:82-88.
Blair E, Al Asedy F, Badawi N, Bower C. Is cerebral palsy associated with birth defects other than cerebral defects? Dev Med Child Neurol. 2007;49:252-258.
Langer JC. Abdominal wall defects. World J Surg. 2003;27:117-124.
Morris RK, Cnossen JS, Langejans M, et al. Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. BMC Pregn Childbirth. 2008;8:33.
Settiyanan T, Wanapirak C, Sirichotiyakul S, et al. Association between isolated abnormal levels of maternal serum unconjugated estriol in the second trimester and adverse pregnancy outcomes. J Matern Fetal Neonat Med. 2016;29:2093-2097.
Kowalczyk TD, Cabaniss ML, Cusmano L. Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. Obstetr Gynecol. 1998;91:396-400.
Nunthapiwat S, Sekararithi R, Wanapirak C, et al. Second trimester serum biomarker screen for fetal aneuploidies as a predictor of preterm delivery: a population-based study. Gynecol Obstetr Invest. 2019;84:326-333.
Chatuphonprasert W, Jarukamjorn K, Ellinger I. Physiology and pathophysiology of steroid biosynthesis, transport and metabolism in the human placenta. Front Pharmacol. 2018;9:1027.
Minsart A-F, Van Onderbergen A, Jacques F, Kurt C, Gillerot Y. Indication of prenatal diagnosis in pregnancies complicated by undetectable second-trimester maternal serum estriol levels. J Prenat Med. 2008;2:27-30.
Singnoi W, Wanapirak C, Sekararithi R, Tongsong T. A cohort study of the association between maternal serum inhibin-A and adverse pregnancy outcomes: a population-based study. BMC Pregn Childbirth. 2019;19:124.
Jelliffe-Pawlowski L, Baer R, Blumenfeld Y, et al. Maternal characteristics and mid-pregnancy serum biomarkers as risk factors for subtypes of preterm birth. Br J Obstetr Gynaecol. 2015;122:1484-1493.
Fitzgerald B, Levytska K, Kingdom J, Walker M, Baczyk D, Keating S. Villous trophoblast abnormalities in extremely preterm deliveries with elevated second trimester maternal serum hCG or inhibin-A. Placenta. 2011;32:339-345.
Redline RW, Minich N, Taylor HG, Hack M. Placental lesions as predictors of cerebral palsy and abnormal neurocognitive function at school age in extremely low birth weight infants (<1 kg). Pediatr Dev Pathol. 2007;10:282-292.
Peris M, Reid SM, Dobie S, Bonacquisto L, Shepherd DA, Amor DJ. First-trimester maternal serum biomarkers and the risk of cerebral palsy. Dev Med Child Neurol. 2021;63:183-189.